<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00085150</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000367333</org_study_id>
    <secondary_id>NCI-04-C-0168</secondary_id>
    <secondary_id>NCI-5903</secondary_id>
    <nct_id>NCT00085150</nct_id>
    <nct_alias>NCT00082004</nct_alias>
  </id_info>
  <brief_title>LMB-2 Immunotoxin in Treating Young Patients With Relapsed or Refractory Leukemia or Lymphoma</brief_title>
  <official_title>Pediatric Phase I Trial of LMB-2 for Refractory CD25-Positive Leukemias and Lymphomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: LMB-2 immunotoxin can locate cancer cells and kill them without harming normal&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying the side effects and best dose of LMB-2 immunotoxin&#xD;
      in treating young patients with relapsed or refractory leukemia or lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the maximum tolerated dose of LMB-2 immunotoxin in pediatric patients with&#xD;
           CD-25 positive relapsed or refractory leukemia or lymphoma.&#xD;
&#xD;
        -  Determine the toxic effects of this drug in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics of this drug, including the terminal elimination serum&#xD;
           half-life, area under the curve, volume of distribution, and relationship to disease&#xD;
           burden, in these patients.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Evaluate the immonogenicity of this drug in these patients.&#xD;
&#xD;
        -  Determine response in patients treated with this drug.&#xD;
&#xD;
        -  Determine changes in lymphocyte subsets, immunoglobulin levels, serum cytokines, and&#xD;
           soluble cytokine receptor levels in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, multicenter study.&#xD;
&#xD;
      Patients receive LMB-2 immunotoxin IV over 30 minutes on days 1, 3, and 5. Treatment repeats&#xD;
      every 28 days for up to 6 courses in the absence of disease progression, neutralizing&#xD;
      antibodies (i.e., &gt; 75% of the activity of 1 µg/mL of LMB-2 immunotoxin), or unacceptable&#xD;
      toxicity. Patients achieving complete remission (CR) receive 2 additional courses beyond CR.&#xD;
      Patients with acute lymphoblastic leukemia also receive cytarabine and hydrocortisone&#xD;
      intrathecally once monthly concurrent with restaging lumbar punctures.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of LMB-2 immunotoxin until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, a&#xD;
      total of 12 patients are treated at that dose level.&#xD;
&#xD;
      Patients are followed weekly for 1 month and then monthly thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 20-40 patients will be accrued for this study within 2-4 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2004</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LMB-2 immunotoxin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of 1 of the following:&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma, including the following subtypes:&#xD;
&#xD;
                    -  Lymphoblastic lymphoma&#xD;
&#xD;
                    -  Burkitt's lymphoma&#xD;
&#xD;
                    -  Large cell lymphoma&#xD;
&#xD;
                    -  Adult T-cell leukemia/lymphoma&#xD;
&#xD;
                    -  Cutaneous T-cell lymphoma&#xD;
&#xD;
                    -  Peripheral T-cell lymphoma&#xD;
&#xD;
               -  Hodgkin's disease&#xD;
&#xD;
               -  Acute myeloid leukemia&#xD;
&#xD;
               -  Chronic myelogenous leukemia&#xD;
&#xD;
               -  Acute lymphoblastic leukemia (ALL)&#xD;
&#xD;
                    -  More than 5% blasts in the bone marrow (i.e., M2 marrow classification)&#xD;
&#xD;
               -  Acute hybrid leukemia, including the following subtypes:&#xD;
&#xD;
                    -  Mixed lineage leukemia&#xD;
&#xD;
                    -  Biphenotypic leukemia&#xD;
&#xD;
                    -  Undifferentiated leukemia&#xD;
&#xD;
          -  CD25-positive (CD25+) disease, meeting 1 of the following criteria:&#xD;
&#xD;
               -  More than 15% of malignant cells are CD25+ by immunohistochemistry with anti-CD25&#xD;
                  antibody&#xD;
&#xD;
               -  More than 30% of malignant cells from a site are CD25+ by fluorescence-activated&#xD;
                  cell sorting analysis&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
          -  Relapsed or refractory disease after at least 1 standard chemotherapy regimen AND 1&#xD;
             salvage regimen&#xD;
&#xD;
          -  No available alternative curative therapies&#xD;
&#xD;
          -  Ineligible for or refused hematopoietic stem cell transplantation OR disease activity&#xD;
             that prohibits the required time to identify a suitable stem cell donor&#xD;
&#xD;
          -  No CNS leukemia or lymphoma, as evidenced by any of the following criteria:&#xD;
&#xD;
               -  Cerebrospinal fluid (CSF) WBC &gt; 5/µl AND confirmation of CSF blasts&#xD;
&#xD;
               -  Cranial neuropathies secondary to underlying malignancy&#xD;
&#xD;
               -  CNS lymphoma detected by radiological imaging&#xD;
&#xD;
                    -  Prior CNS involvement with no current evidence of CNS malignancy allowed&#xD;
&#xD;
          -  No isolated testicular ALL&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  6 months to 21 years&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-3 (≥ 12 years of age)&#xD;
&#xD;
          -  Lansky 40-100% (&lt; 12 years of age)&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Pancytopenia due to disease allowed&#xD;
&#xD;
          -  For patients without bone marrow involvement:&#xD;
&#xD;
               -  Absolute neutrophil count &gt; 1,000/mm^3&#xD;
&#xD;
               -  Platelet count &gt; 50,000/mm^3 (transfusion independent)&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  AST and ALT ≤ 5 times upper limit of normal&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Hepatitis C antibody negative&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine clearance ≥ 60 mL/min OR&#xD;
&#xD;
          -  Creatinine, meeting the following age-related criteria:&#xD;
&#xD;
               -  ≤ 0.8 mg/dL (≤ 5 years of age)&#xD;
&#xD;
               -  ≤ 1.0 mg/dL (6 to 10 years of age)&#xD;
&#xD;
               -  ≤ 1.2 mg/dL (11 to 15 years of age)&#xD;
&#xD;
               -  ≤ 1.5 mg/dL (&gt; 15 years of age)&#xD;
&#xD;
          -  Calcium 2.0-2.9 mmol/L&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Ejection fraction ≥ 45% by MUGA OR&#xD;
&#xD;
          -  Shortening fraction ≥ 28% by echocardiogram&#xD;
&#xD;
        Pulmonary&#xD;
&#xD;
          -  Oxygen saturation ≥ 90%&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Sodium 130-150 mmol/L&#xD;
&#xD;
          -  Potassium 3.0-5.5 mmol/L&#xD;
&#xD;
          -  Magnesium 0.5-1.23 mmol/L&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No clinically significant unrelated systemic illness that would preclude study&#xD;
             participation&#xD;
&#xD;
          -  No conditions that would preclude study compliance&#xD;
&#xD;
          -  No serum that neutralizes &gt; 75% of the activity of 1 μg/mL of LMB-2 immunotoxin in&#xD;
             tissue culture (due to either anti-toxin or anti-mouse immunoglobulin G antibodies)&#xD;
&#xD;
          -  No active graft-vs-host disease (i.e., off immunosuppression)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Prior autologous bone marrow transplantation (BMT) allowed&#xD;
&#xD;
          -  At least 100 days since prior allogeneic BMT&#xD;
&#xD;
          -  At least 1 week since prior colony-stimulating factors (e.g., filgrastim [G-CSF],&#xD;
             sargramostim [GM-CSF], or epoetin alfa)&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  At least 2 weeks since prior chemotherapy (4 weeks for nitrosoureas) except&#xD;
             intrathecal chemotherapy&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Concurrent corticosteroids allowed provided the dose has been stable for the past week&#xD;
             and does not increase during study treatment&#xD;
&#xD;
               -  Tapering or discontinuation of steroids allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy unless &lt; 10% of marrow is irradiated and&#xD;
             measurable disease exists outside the radiation port&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Recovered from all prior therapy&#xD;
&#xD;
          -  At least 30 days since prior investigational agents&#xD;
&#xD;
          -  Concurrent oral supplementation to maintain normal electrolyte levels allowed&#xD;
&#xD;
          -  No concurrent anticoagulation therapy for disease-related conditions&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alan S. Wayne, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Winship Cancer Institute of Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231-2410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doernbecher Children's Hospital at Oregon Health &amp; Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239-3098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2007</verification_date>
  <study_first_submitted>June 10, 2004</study_first_submitted>
  <study_first_submitted_qc>June 10, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2004</study_first_posted>
  <last_update_submitted>April 29, 2015</last_update_submitted>
  <last_update_submitted_qc>April 29, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2015</last_update_posted>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>childhood Burkitt lymphoma</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunotoxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

